Case report: Adult with bipolar disorder and autism treated with ketamine assisted psychotherapy.
Christopher P Harris, Becky Jones, Kathryn Walker, Meredith S Berry
Frontiers in Psychiatry 2024 DOI: 10.3389/fpsyt.2024.1322679 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 29-year-old man with bipolar disorder, Autism Spectrum Disorder, and type 2 diabetes |
| Intervention | Ketamine-assisted psychotherapy |
| Dose | 6 initial IV infusions over 1 month followed by 2 booster IV infusions |
| Duration | 1 month of initial infusions, with booster infusions afterward |
| Topics | Ketamine Esketamine Psychedelic-assisted therapy |
| Keywords | Autism spectrum disorder Bipolar disorder Case report Ketamine assisted psychotherapy Psychopharmacology Kap Ketamine treatment Behavioral therapy Bd Case study |
| Citations | 4 |
| Key findings | Ketamine assisted psychotherapy led to dramatic reductions in anger outbursts, anxiety, suicidality, and depression in a patient with bipolar disorder and Autism Spectrum Disorder. |
Abstract
Evidence has increased in recent years regarding the potential for ketamine to serve as a novel treatment option for a range of conditions, particularly depression (unipolar and bipolar). However, research regarding ketamine as a potential therapeutic for Autism Spectrum Disorder (ASD) is lacking, despite high overlap with bipolar depression and theoretical foundations for its use. A 29-year-old man with bipolar disorder and Autism Spectrum Disorder, type 2 diabetes, presented with mood swings and suicidal thoughts, and anger outbursts occurring daily. The patient was referred by a psychiatrist due to irritability and outbursts during the previous 5 months. These outbursts were unable to be controlled by the medications prescribed, included yelling and screaming, and the patient was unable to speak with the psychiatrist. The patient underwent ketamine assisted psychotherapy with 6 initial IV infusions of ketamine over a 1 month period followed by 2 booster IV ketamine infusions. Following ketamine treatment, dramatic reductions in outbursts were observed as well as reductions in anxiety, suicidality, and depression scores. This case study adds to the scant literature regarding ketamine treatment for individuals with bipolar disorder and ASD. We did not find ASD to be a contraindication for IV ketamine and ketamine assisted psychotherapy. Reductions in anger outbursts, anxiety, suicidality, and depression suggest ketamine treatment might be tailored to individuals with bipolar disorder and ASD, and additional systematized research is warranted. Although potential mechanisms of action are not clear, these data add to the discussion regarding clinical practice considerations and the potential for ketamine to improve quality of life and associated metrics.
Comparable studies
Other case reports and case series on ketamine and psychedelic-assisted therapy, most cited first.
Citations in the library
Cited by 4
- Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review. Clinical Psychology Review February 2, 2026
- Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications. Pharmaceutics January 8, 2026
- Centering prayer in the treatment of bipolar disorder World Journal of Advanced Research and Reviews March 30, 2024
- Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges Pharmacological Research August 26, 2026
Cites 9
- Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial British medical journal February 2, 2022
- Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT) The International Journal of Neuropsychopharmacology December 4, 2021
- Ketamine in Bipolar Disorder: A Review Neuropsychiatric Disease and Treatment November 1, 2020
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review - CORRIGENDUM. BJPsych Open January 18, 2022
- Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Journal of autism and developmental disorders April 2021
and 4 more in the library